newsfilter
← Latest News
GlobeNewswire·

Following Significant Advances at ASCO, Amplia Therapeutics Provides Letter to Shareholders Highlighting the Potential Opportunities for Combination with KRAS Inhibition in Pancreatic Cancer

Melbourne, Australia, June 22, 2026 (GLOBE NEWSWIRE) -- Amplia Therapeutics Limited ((ASX:ATX, OTCQB:INNMF), ("Amplia" or the "Company") provides a letter to shareholders from CEO and Managing Director